CASTLE BIOSCIENCES INC

Tickers
CSTL
Headquarters
Not recorded
SEC CIK
0001447362
Website
Not recorded

Closing prices

Latest close, 38.51

Closing prices for CSTL249 stored closes for CSTL from 3 Nov 2025 to 29 Oct 2026. Lowest 18.15 on 13 May 2026, highest 43.04 on 26 Jan 2026, latest 38.51 on 29 Oct 2026.Close10.0020.0030.0040.0050.003 Nov 20251 May 202629 Oct 2026
249 stored closes, oldest first. End of day, not intraday.

Drugs

No drugs from this company are tracked yet.

FDA-approved applications

No Drugs@FDA application has a sponsor name that matches this company.

Data provided by the U.S. Food and Drug Administration (Drugs@FDA). Sponsors are matched to companies by name; subsidiaries do not link.

Catalysts

No catalysts yet. Editors add each date together with its source.

Deals

No approved deals involve this company yet.

Reported fundamentals (SEC XBRL)

Latest value of each metric as reported to the SEC
MetricReported valuePeriodFiling
Revenue103,546,000 USD 1 Apr 2026 to 30 Jun 2026 FY2026 Q210-Q for Revenue on sec.gov (opens in a new tab)Filed
Net income (loss)−2,060,000 USD 1 Apr 2026 to 30 Jun 2026 FY2026 Q210-Q for Net income (loss) on sec.gov (opens in a new tab)Filed
Research and development expense14,543,000 USD 1 Apr 2026 to 30 Jun 2026 FY2026 Q210-Q for Research and development expense on sec.gov (opens in a new tab)Filed
Operating expenses24,069,000 USD 1 Jan 2021 to 31 Mar 2021 FY2021 Q110-Q for Operating expenses on sec.gov (opens in a new tab)Filed
Cash and cash equivalents62,116,000 USD At 30 Jun 2026 FY2026 Q210-Q for Cash and cash equivalents on sec.gov (opens in a new tab)Filed
Short-term investments and marketable securities204,689,000 USD At 30 Jun 2026 FY2026 Q210-Q for Short-term investments and marketable securities on sec.gov (opens in a new tab)Filed
Total liabilities91,147,000 USD At 30 Jun 2026 FY2026 Q210-Q for Total liabilities on sec.gov (opens in a new tab)Filed
Stockholders' equity470,030,000 USD At 30 Jun 2026 FY2026 Q210-Q for Stockholders' equity on sec.gov (opens in a new tab)Filed
Common shares outstanding (cover page)30,549,507 shares At 23 Jul 2026 FY2026 Q210-Q for Common shares outstanding (cover page) on sec.gov (opens in a new tab)Filed

History

Revenue, newest period first
PeriodReported valueFiling
1 Apr 2026 to 30 Jun 2026 FY2026 Q2103,546,000 USD10-Q filed 30 Jul 2026 on sec.gov (opens in a new tab)Filed
1 Jan 2026 to 31 Mar 2026 FY2026 Q183,679,000 USD10-Q filed 6 May 2026 on sec.gov (opens in a new tab)Filed
1 Jan 2025 to 31 Dec 2025 FY2025344,229,000 USD10-K filed 26 Feb 2026 on sec.gov (opens in a new tab)Filed
1 Jul 2025 to 30 Sep 2025 FY2025 Q383,043,000 USD10-Q filed 3 Nov 2025 on sec.gov (opens in a new tab)Filed
1 Apr 2025 to 30 Jun 2025 FY2026 Q286,188,000 USD10-Q filed 30 Jul 2026 on sec.gov (opens in a new tab)Filed
1 Jan 2025 to 31 Mar 2025 FY2026 Q187,988,000 USD10-Q filed 6 May 2026 on sec.gov (opens in a new tab)Filed
1 Jan 2024 to 31 Dec 2024 FY2025332,069,000 USD10-K filed 26 Feb 2026 on sec.gov (opens in a new tab)Filed
1 Jul 2024 to 30 Sep 2024 FY2025 Q385,782,000 USD10-Q filed 3 Nov 2025 on sec.gov (opens in a new tab)Filed

The newest 12 periods of each metric are listed; older ones are on sec.gov.

Values as reported in the company's XBRL filings to the SEC, one per calendar period (SEC frames); not adjusted, not audited by HealthTrade, and not investment advice.

Source: SEC XBRL company facts (opens in a new tab) · Licence: public-domain · as of 2026-10-25 · read

SEC filings

SEC filings from CASTLE BIOSCIENCES INC, newest first
FormFiledWhat it coversDocument
4 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 30 Oct 2026 on sec.gov (opens in a new tab)Filing index for 0001628280-26-068566 (opens in a new tab)
4 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 28 Oct 2026 on sec.gov (opens in a new tab)Filing index for 0001628280-26-067887 (opens in a new tab)
4Event 19 Oct 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 21 Oct 2026 on sec.gov (opens in a new tab)Filing index for 0001628280-26-066724 (opens in a new tab)
4Event 12 Oct 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 14 Oct 2026 on sec.gov (opens in a new tab)Filing index for 0001628280-26-065870 (opens in a new tab)
4Event 5 Oct 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 7 Oct 2026 on sec.gov (opens in a new tab)Filing index for 0001628280-26-065327 (opens in a new tab)
4Event 1 Oct 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 5 Oct 2026 on sec.gov (opens in a new tab)Filing index for 0001628280-26-064912 (opens in a new tab)
4Event 29 Sep 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 1 Oct 2026 on sec.gov (opens in a new tab)Filing index for 0001628280-26-064267 (opens in a new tab)
4Event 21 Sep 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 23 Sep 2026 on sec.gov (opens in a new tab)Filing index for 0001628280-26-063221 (opens in a new tab)
4Event 14 Sep 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 16 Sep 2026 on sec.gov (opens in a new tab)Filing index for 0001628280-26-062255 (opens in a new tab)
4Event 11 Sep 2026 Insider transaction report (Form 4) View Insider transaction report (Form 4) filed 15 Sep 2026 on sec.gov (opens in a new tab)Filing index for 0001628280-26-062047 (opens in a new tab)

Source: SEC EDGAR. Each row links to the filing on sec.gov.

Related news

No recent headlines mention this company.

Last 90 days of Form 4 filings, from 3 Aug 2026 (US Eastern dates).

Buys code P
None in this period
Sells code S
57 transactions, 195,403 shares, $6,254,051.42
Other all other codes
8 transactions: grants, exercises, tax withholding, gifts and similar

Last transaction:

Insider filings are public records and are not a recommendation. Source: SEC EDGAR.

Sources

Nothing on this page is investment advice.